Mentors & Advisors
Director, Gastroenterology Drug Discovery Unit, Research
Takeda Pharmaceutical Company, Ltd.
In the face of an aging society, we hope that the proposals will be based on a unique concept that is not captured by conventional wisdom, and has the aim of taking on the challenge of providing innovative solutions to healthcare issues such as treatments for diseases with high unmet medical needs such as neurodegenerative/psychiatric disease, cancer, gastrointestinal disease, immune/inflammation and rare diseases.
Senior Specialist, Strategy and Commercial Excellence
We look forward to businesses that create services and solutions that will resolve medical issues that Japan faces, such as the aging society, increasing medical costs, and further improvement of the quality of life for patients.
Rx+ Business Accelerator
Astellas Pharma Inc.
We look forward to services that will improve medical scenes (Patient Journey: Diagnosis, Prevention, Treatment, and Prognostic Management), treatment, prevention effects experienced by patients, improvements in treatment and prevention effects, and technologies/services such as digital, software, medical devices and behavioral therapies that may contribute to the healthcare field by utilizing big data that can be collected in large quantities. Even if you cannot implement your businesses with the technologies and ideas you possess at this time, we welcome those business plans that may be implemented through integration of other technologies and services.
Manager, Home Healthcare Research, Development & Technology Division
TEIJIN PHARMA LTD.
We anticipate for services and products that use smartphones, apps, and wearable devices to resolve unmet needs in the healthcare field. We emphasize the uniqueness of services/products and the impact on the market. We would like to see solutions-based ideas rather than measurement and diagnostic services and products. In the future, we aim to create innovative and new healthcare services by combining the ideas of start-up companies with our knowledge.
Toshiro Sakaki, Ph.D.
Principle Research Scientist, Future Design Department
Mitsubishi Tanabe Pharma Corporation
We hope that this accelerator will foster an environment for new combinations of businesses between healthcare/medical field and other fields, and that these businesses will resolve issues in the world.
Director, Research Beyond Borders and R&D Liason, Kobe Pharma Research Institute
Nippon Boehringer Ingelheim Co., Ltd.
Boehringer Ingelheim believes that supporting entrepreneurial scientists is important when innovating. We hope to co-create innovations in fields where synergies are expected across fields (fibrosis, immune control, regenerative medicine, gene therapy, and microbiomes) as well as in new fields where unmet needs are high (hearing impairment, osteoarthritis, ophthalmology, rare diseases, and infectious diseases).
Manager, Corporate Strategy Department
Eisai Co., Ltd.
Our company is now working to provide solutions to improve access to healthcare in general (prevention, treatment, and care). In particular, dementia of the Alzheimer type has high unmet needs and solutions other than medication are important. We hope that this program will be an epoch-making project that will fill the gap in healthcare and improve patients’ health and daily lives. We also hope that this program will lead to the creation of new businesses, such as services that will enable people to detect dementia at an early stage by identifying warning signs of dementia in their daily lives.
Hirokazu Annoura, Ph.D.
Principal, R&D Planning & Management Department, Resource Planning Group
DAIICHI SANKYO COMPANY, LTD.
Pharmaceutical R&D has evolved from a conventional in-house model to a hybrid model in collaboration with external R&D through open innovation and crowdsourcing. We hope that this program will accelerate the creation of new business opportunities and lead to the commercialization of new services in advanced pharmaceuticals and healthcare fields that will transform the standard of care.
Business Planning Manager, Global Corporate Planning
Sumitomo Dainippon Pharma Co., Ltd.
We await for a wide range of technologies and services that will help people that will help people “live long healthily and happily” and not limited to pharmaceuticals and healthcare.
Manager, Venture Group, Emerging Technology and Business Development Office
Mitsubishi Chemical Holdings Corporation
We expect to collaborate with the startups working on “Around the Pill” and “Beyond the Pill” material related solutions for healthcare.
Makoto Asakawa, Ph.D, MBA
Director, Section Head of Strategic Planning, Digital Intelligence Dept.
SHIONOGI & CO., LTD.
We are waiting for a wide range of technologies and services that will help people to “enjoy and live long, healthy lives” without being bound to pharmaceuticals and healthcare.
Life Science Innovation Network Japan, Inc.
We would like to provide a wide-range of support to startups through LINK-J platforms.
General Manager, Business Strategy DepartmentTIPNESS LIMITED
TIPNESS LIMITED will create a new business model including conventional facility type services. With “conditioning” as a keyword, we are providing an appropriate solution to visualize the current state of mind and body and to get closer to the target efficiently. We are looking forward to meeting people who have various new ideas centered on conditioning.
Group Manager, Pharmaceutical Business Strategic Planning, Pharmaceutical Product
Taisho Pharmaceutical Co., Ltd.
Our mission is to contribute to society by creating and offering superior medicines and health-related products as well as health-related information and services in socially responsible ways that enrich people’s lives by improving health and beauty.
During the dramatic progress of the Fourth Industrial Revolution utilizing IT and artificial intelligence (AI), we expect that this will be an opportunity to create new value with specialists in biotechnology, healthcare and different fields.
Nobuya Ishii, Ph.D.
Department Manager, Science & Technology Intelligence Dept. Project & Lifecycle Management Unit
Chugai Pharmaceutical Co., Ltd.
We look forward to maximizing value and efficiency of drugs, as well as research and develop new digital tools such as digital therapy and digital biomarkers that will lead to expansion of the scope of drugs in the future medical environment, in which precision medicine and personalized medicine can be achieved.
Leader, CORPORATE SCIENCE RESEARCH
With the integration of Biotechnology and IT, we expect not only to make efforts in contributing to human health maintenance and preventive care in the life science field. We also look forward to innovations that will “disrupt” the manufacturing in food, agriculture and fishery industries.
Chief Marketing Officer
We look forward to be able to consider collaboration with participating startups. By working with startups, we can solve essential issues in healthcare and prevention with innovation that integrates technology, science, data, and process. We can then expand the market to not only Japan, but to the global market. We are hoping for a collaboration that will lead to a powerful business creation to solve medical issues that may arise in the next 5 to 10 years. Since we are also a startup, we hope to be able to create value in the world by building next-generation medical services together with other startups.
Head of Open Innovation Center Japan, Open Innovation Center Japan
Bayer Yakuhin, Ltd.
Bayer Yakuhin, Ltd. believes that true innovation is not limited to technological development but also includes the creation of new values. We expect to be able to promote the creation of innovation with startups and contribute to patients’ better lives through diverse cooperation with startups in the healthcare and digital field.
Takayuki Yamaguchi, Ph.D.
Senior Manager, CPRI, Project & Portfolio Management, Preclinical
Japan Tobacco Inc.
In the 100-year life era, the way of “medical care” is currently undergoing a major transformation period. In addition to the development of innovative drugs for current unmet medical needs, we believe that the integration of IT and biotechnology/healthcare is essential to the creation of a new treatment paradigm that will head for preemptive medical care, precision medicine/permanent cure, and regenerative medicine. We look forward to meeting startups with innovative technologies and ideas.
Norihiko Shiraishi, Ph.D.
Manager, R&D Planning Department, R&D Division
Kyowa Hakko Kirin Co., Ltd.
We do not even need to quote the Red Queen hypothesis; we must continue to have the mindset to incorporate new technologies as well as further improving cultivated core technologies such as antibodies and small molecules. In addition to improving speed and accuracy at all stages of research, development, and manufacturing through new technologies and analysis, we are looking forward to discontinuous innovations in approaches to diseases that start with phenomena that can be found by new devices and analysis.
Research and Development Division
Sunstar’s business theme is “Mouth & Body (oral and overall health)”. As recognition of the the effects of oral care on overall health is increasing, “Prevention of Oral Fail”and “Oral hygiene, prevention of body discomfort, and systemic illness by maintenance of oral function” become very big issues Through integration of IT technology, biotechnology, and healthcare, we hope to become a place for co-creation with everyone who is willing to create new value to promote a healthy lifespan.
President and Group CEO,
Digital Garage, Inc.
Chairman & Director,
Digital Garage, Inc.
MIT Media Lab
Inamoto & Co.
Faculty of Environment and Information Studies,Graduate School of Media and Governance, Keio University
Pinterest & Obvious Ventures Adviser
Chief Entrepreneurial Officer and Professor of Practice, Cornell Tech
Board Chair, Rhizome Foundation